Advertisement

Topics

Sanofi in $675 million deal to expand multiple sclerosis franchise

09:00 EST 9 Nov 2017 | thePharmaLetter

French pharma major Sanofi, which already has two blockbuster multiple sclerosis (MS) drugs in the form…

Original Article: Sanofi in $675 million deal to expand multiple sclerosis franchise

NEXT ARTICLE

More From BioPortfolio on "Sanofi in $675 million deal to expand multiple sclerosis franchise"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...